奥佳华智能健康科技集团股份有限公司 2024 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2024 年度独立董事述职报告 （独立董事：王志强） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 在 2024 年的工作中，忠实、勤勉地履行独立董事职务。现将本人 2024 年度的履 职情况报告如下： 一、基本情况 本人王志强，中国国籍，无境外居留权，男，1967 年出生，博士研究生学 历，厦门大学管理学院教授、博士生导师。现兼任华厦眼科医院集团股份有限公 司独立董事、厦门厦工机械股份有限公司独立董事。 二、2024 年度履职概况 （一）出席公司董事会及股东大会情况 2024 年度，公司董事会共召开 5 次会议，其中 1 次现场+通讯会议，4 次通 讯会议，本人均亲自出席，出席股东大会 2 次。本人恪尽职守、勤勉尽责，详细 了解公司运作情况，认真审议董事会各项议案， ...

奥佳华智能健康科技集团股份有限公司 2024 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2024 年度独立董事述职报告 （独立董事：蔡天智） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 在 2024 年的工作中，忠实、勤勉地履行独立董事职务。现将本人 2024 年度的履 职情况报告如下： 一、基本情况 本人蔡天智，中国国籍，无境外居留权，男，1960 年出生，本科学历，白 求恩医科大学（现为吉林大学）医学专业。曾任中国医药保健品进出口商会副秘 书长、科技发展部和绿色中药管理办公室主任、业务协调三部（医疗器械部）主 任。现任中国国际旅行卫生保健协会医疗物资与医疗合作分会会长、白求恩医科 大学北京校友会副会长，兼任奥美医疗用品股份有限公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、2 ...

2024 年度独立董事述职报告 （独立董事：曹阳） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 在 2024 年的工作中，忠实、勤勉地履行独立董事职务。现将本人 2024 年度的履 职情况报告如下： 一、基本情况 本人曹阳，中国国籍，无境外居留权，男，1965 年出生，硕士研究生学历， 教授级高级工程师，博士生导师。现任建科环能科技有限公司建筑环境与能源检 测院副院长。 奥佳华智能健康科技集团股份有限公司 2024 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2024 年度，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。 二、2024 年度履职概况 （一）出席公司董事会及股东大会情况 2024 年度，公司董事会共召开 5 次会议，其中 1 次现场+通讯会议，4 次通 讯会议，本人均亲自出席，出席股东大会 1 次 ...

特此公告。 奥佳华智能健康科技集团股份有限公司 董 事 会 2025 年 4 月 28 日 奥佳华智能健康科技集团股份有限公司董事会 关于独立董事独立性自查情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等规定，奥佳华智能健康科技集团股份有限公司（以下简称"公 司"）董事会，就公司在任独立董事蔡天智、曹阳、王志强的独立性情况进行评 估并出具如下专项意见： 经核查独立董事蔡天智、曹阳、王志强的任职经历以及签署的相关自查性文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律法规及《公司章程》中对独立董事独立性的相关要求。 ...

一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-15 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 关于召开公司 2024 年年度股东大会的通知 本公司及董事会全体董事保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 根据奥佳华智能健康科技集团股份有限公司（以下简称"公司"）2025 年 4 月 27 日召开的第六届董事会第八次会议决议，公司董事会定于 2025 年 5 月 20 日（星 期二）下午 14:30 在厦门市湖里区安岭二路 31-37 号公司八楼会议室召开公司 2024 年年度股东大会（以下简称"本次股东大会"），现将有关事项通知如下： 4、本次股东大会召开时间： （1）现场会议召开时间：2025 年 5 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-16 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 第六届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）第六届监事会 第七次会议通知以电话、传真及电子邮件等方式于 2025 年 4 月 17 日发出。会议 于 2025 年 4 月 27 日上午 11:00 在厦门市湖里区安岭二路 31-37 号公司八楼会议 室以现场方式召开，并获得全体监事确认。本次会议应到监事 3 名，实际出席会 议监事 3 名。本次会议由公司监事会主席杨青女士主持，会议符合《中华人民共 和国公司法》和公司章程的有关规定。 经全体监事认真审议，以现场表决方式通过了如下决议： 一、会议以 3 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度监事会工作报告的议案》，本议案需提交 2024 年年度股东大会审议。 二、会议以 3 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-04 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 根据立信会计师事务所（特殊普通合伙）审计结果，2024 年度公司实现营 业收入 483,332.19 万元，同比下降 3.92%；归属于上市公司股东的净利润 6,423.87 万元，同比下降 37.76%。 二、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度募集资金存放与使用情况的专项报告的议案》。 本议案已经公司董事会审计委员会审议通过。 三、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度内部控制自我评价报告的议案》。 本议案已经公司董事会审计委员会审议通过。 四、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度利润分配预案的议案》，本议案需提交公司 2024 年年度股东大会审议。 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-07 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 若在利润分配预案公布后至实施前，公司总股本发生变动的，则以未来实施 利润分配方案时股权登记日的总股本为基数，按照分配比例不变的原则对分配总 额进行调整。 上述利润分配方案将于股东大会审议通过之日起两个月内实施完毕。 1/ 3 3、如本项议案最终获得股东大会审议通过，公司 2024 年度现金分红总额预 计为 62,347,675.20 元（含税），占公司 2024 年度归属于上市公司股东净利润的 97.06%。 二、现金分红方案的具体情况 （一）公司 2024 年度利润分配预案未触及其他风险警示情形 1、最近三个会计年度利润分配情况： 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开了第六届董事会第八次会议及第六 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,147,544,843.46, representing a year-over-year increase of 9.17% compared to ¥1,051,117,744.65 in the same period last year[5]. - Net profit attributable to shareholders decreased by 60.04% to ¥1,997,005.34 from ¥4,996,914.97 in the previous year[5]. - The company reported a basic earnings per share of ¥0.003, down 70.00% from ¥0.01 in the same period last year[5]. - Net profit for the current period was ¥1,721,942.79, a decrease of 66.19% from ¥5,103,538.76 in the previous period[25]. - Total operating revenue for the current period reached ¥1,147,544,843.46, an increase of 9.15% compared to ¥1,051,117,744.65 in the previous period[24]. - Total operating costs amounted to ¥1,145,349,011.63, up from ¥1,060,968,546.72, reflecting a rise of 7.97%[24]. - Total comprehensive income for the current period was ¥14,133,831.65, a significant increase from ¥88,551.05 in the previous period[26]. Cash Flow and Investments - The net cash flow from operating activities improved by 49.46%, reaching -¥93,972,745.38, compared to -¥185,951,326.25 in Q1 2024[5]. - Cash flow from operating activities showed a net outflow of ¥93,972,745.38, an improvement from a net outflow of ¥185,951,326.25 in the previous period[28]. - The company generated ¥1,290,124,316.00 in cash inflows from operating activities, compared to ¥1,155,022,311.60 previously, indicating a growth of 11.65%[27]. - The net cash flow from investing activities decreased by 41.95% to ¥98,738,649.97 compared to ¥170,091,100.29 in Q1 2024[14]. - The net cash flow from investing activities was ¥98,738,649.97, down from ¥170,091,100.29, reflecting a decrease of 42.00%[28]. Assets and Liabilities - The total assets as of March 31, 2025, were ¥7,386,058,803.08, a decrease of 2.57% from ¥7,581,151,714.95 at the end of the previous year[5]. - The company’s total liabilities increased significantly, with current liabilities due within one year rising by 263.73% to ¥578,655,982.47[9]. - Total liabilities decreased to ¥2,903,222,418.51 from ¥3,114,262,583.57, a reduction of about 6.8%[22]. - Total current assets decreased to ¥3,988,725,331.88 from ¥4,205,465,727.75, a decline of approximately 5.2%[20]. - The company’s cash and cash equivalents decreased to ¥670,709,325.85 from ¥799,276,742.37, a decline of approximately 16.1%[20]. - The company reported a total asset decrease to ¥7,386,058,803.08 from ¥7,581,151,714.95, a decline of about 2.6%[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,531[16]. - The largest shareholder, Zou Jianhan, holds 20.47% of shares, totaling 127,620,000 shares, with 32,000,000 shares pledged[16]. - The number of shares held by the top 10 shareholders represents a significant concentration of ownership, with the top two shareholders holding a combined 38.50%[16]. Other Information - The company experienced a significant increase in receivables financing, which rose by 9809.42% to ¥27,232,674.99 from ¥274,816.00[9]. - The company reported a decrease in financial expenses by 233.69%, resulting in a financial income of -¥20,755,256.40 compared to ¥15,524,364.16 in the previous year[12]. - The company’s investment income decreased by 67.07% to ¥7,180,767.12 from ¥21,805,060.20 in the previous year[12]. - The company has not reported any new product developments or market expansion strategies in the current conference call[18]. - The company reported a significant increase in interest income, which rose to ¥10,537,101.54 from ¥2,675,485.60, marking a growth of 293.36%[25].

Financial Performance - The company's operating revenue for 2024 was ¥4,833,321,898.13, a decrease of 3.92% compared to ¥5,030,460,330.75 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥64,238,678.27, down 37.76% from ¥103,203,187.17 in 2023[19] - The net cash flow from operating activities significantly dropped by 85.45% to ¥130,209,055.41 from ¥895,115,094.07 in the previous year[19] - Basic earnings per share for 2024 were ¥0.10, a decline of 41.18% compared to ¥0.17 in 2023[19] - Total assets at the end of 2024 were ¥7,581,151,714.95, reflecting a decrease of 5.47% from ¥8,019,424,770.29 at the end of 2023[19] - The net assets attributable to shareholders decreased by 3.19% to ¥4,433,152,870.49 from ¥4,579,259,999.09 in 2023[19] - The weighted average return on net assets for 2024 was 1.43%, down from 2.24% in 2023[19] - The net profit after deducting non-recurring gains and losses was ¥24,348,249.49, a decrease of 20.88% from ¥30,774,523.87 in 2023[19] Revenue Breakdown - The main business revenue accounted for ¥4.68 billion, representing 96.79% of total revenue, down 4.73% from ¥4.91 billion in 2023[55] - Health massage products generated ¥3.72 billion, which is 79.59% of main business revenue, showing a slight increase of 0.60% from ¥3.70 billion in 2023[56] - The sales of massage chairs reached ¥2.05 billion, making up 43.75% of main business revenue, a decline of 5.34% from ¥2.16 billion in 2023[55] - The revenue from massage small appliances increased by 8.96% to ¥1.68 billion, representing 35.84% of main business revenue[56] - Domestic sales were approximately ¥1.44 billion, accounting for 30.75% of total revenue, down 5.70% from ¥1.53 billion in 2023[56] - International sales were about ¥3.24 billion, making up 69.25% of total revenue, a decrease of 4.30% from ¥3.39 billion in 2023[56] Market Expansion and Product Development - The company achieved over 50% revenue contribution from its own brand during the reporting period, emphasizing its focus on the health industry and autonomous brand development[28] - The flagship massage chair OG-9598 was launched, featuring a pioneering 5D massage mechanism and AI algorithms, achieving high sales despite its premium price[29] - The company expanded its offline market presence by entering new growth channels such as Sam's Club and Costco, enhancing its competitive position[30] - The brand's net profit increased by 106.89% year-over-year, indicating a significant improvement in profitability during the reporting period[30] - The company is actively exploring new markets along the Belt and Road Initiative, successfully entering multiple countries[28] - The introduction of new products in the mid-range and high-value segments has strengthened the company's competitive edge in the market[29] Research and Development - The company invested 232 million yuan in R&D during the reporting period, focusing on AI algorithms and health detection software[34] - The company has accumulated 2,292 authorized patents, with 1,340 being valid, indicating strong innovation capabilities[34] - The company is focusing on enhancing its "AI + massage" strategy, integrating advanced technologies for personalized health management services[52] - The number of R&D personnel increased by 4.16% to 827, with the proportion of R&D personnel in the total workforce rising to 9.76%[67] Cash Flow and Financial Management - Operating cash inflow decreased by 15.82% to ¥4,760,712,027.04, while operating cash outflow decreased by 2.72% to ¥4,630,502,971.63, resulting in a net cash flow of ¥130,209,055.41, down 85.45% year-on-year[68] - Investment cash inflow surged by 675.57% to ¥1,655,164,383.18, while investment cash outflow increased by 121.83% to ¥1,263,755,921.05, leading to a net cash flow of ¥391,408,462.13[68] - The company's financial expenses saw a significant increase of 631.97% due to a substantial decrease in foreign exchange gains[66] - The company reported an investment income of ¥67,478,588.43, which constituted 73.87% of the total profit, primarily from foreign exchange settlements and structured deposit returns[70] Corporate Governance and Management - The company has a governance structure that complies with relevant laws and regulations, ensuring independence from its controlling shareholders[111] - The company held its annual general meeting with a 42.99% investor participation rate, approving key financial reports and budget plans[114] - The company has a total of 8 directors, with the chairman holding 127,620,000 shares, representing approximately 52.5% of the total shares held by management[116] - The company has maintained its management team since 2010, with the current term ending in September 2026[116] - The company has a diverse management team with backgrounds in various fields, including finance, engineering, and healthcare[118][120] Environmental Compliance - The company has maintained compliance with environmental protection laws and standards, including the "Environmental Protection Law of the People's Republic of China" and various industry standards[150] - The wastewater treatment facility at the subsidiary, Zhangzhou Mengfali, processes wastewater through pre-treatment and a complete flotation system, with a total discharge of 153,000 tons per year[151] - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring data meeting standards during the reporting period[153] - The company has established an emergency response plan for environmental incidents, enhancing its capability to handle such events[154] Social Responsibility - The brand "OGAWA" received six awards during the International Consumer Rights Day event, including "National Leading Brand in Massage Chair Industry" and "National Quality Assurance Product," reflecting strong consumer recognition[161] - The company donated over RMB 200,000 to support flood relief and community development, including a specific donation of RMB 1 million for cardiac rescue projects at Xiamen University First Affiliated Hospital[163]